Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic indexJagath R. Junutula, William Mallet, Helga Raab et al.|Nature Biotechnology|2008Cited by 1.4k
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugatesBen‐Quan Shen, Jagath R. Junutula, Keyang Xu et al.|Nature Biotechnology|2012Cited by 997
Identification of Heregulin, a Specific Activator of p185 <sup>erbB2</sup>William E. Holmes, Richard Vandlen, H. Michael Shepard et al.|Science|1992Cited by 964
<b>Endocytosis and Sorting of ErbB2 and the Site of Action of Cancer Therapeutics Trastuzumab and Geldanamycin</b>Cary D. Austin, Richard H. Scheller, Ann M. De Mazière et al.|Molecular Biology of the Cell|2004Cited by 489
High cell-surface density of HER2 deforms cell membranesInhee Chung, Mark X. Sliwkowski|Nature Communications|2016Cited by 78